SLN Silence Therapeutics
- 21.880
- +0.275+1.27%
Silence Therapeutics News
Silence Therapeutics Announces Retirement of Alistair Gray From Board of Directors
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their
Express News | Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were lower Tuesday morning, declining 0.67% to 1,332.69 on the S&P Europe Select ADR Index. From continental Europe, the gainers were
Silence Therapeutics Announces Upcoming AGM
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week trending moderately higher Monday morning, rising 0.53% to 1,352.74 on the S&P Europe Select ADR Index. From cont
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European equities traded in the US as American depositary receipts were lower Friday morning, falling 0.66% to 1,356.48 on the S&P Europe Select ADR Index. The index is poised to close the week down n
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosingLONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc, Na
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Wednesday morning, rising 0.18% to 1,370.27 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading
European equities traded in the US as American depositary receipts opened the week modestly lower Monday morning, declining 0.23% to 1,353.40 on the S&P Europe Select ADR Index. From continental Europ
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Express News | HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading
European equities traded in the US as American depositary receipts were slightly lower Friday morning, falling 0.19% to 1,359.70 on the S&P Europe Select ADR Index. Despite the decline, the index is s
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, a
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking moderately lower Thursday morning, falling 0.75% to 1,362.82 on the S&P Europe Select ADR Index. From continental Europ
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
Silence Therapeutics (SLN) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $42 to $75.
Analysis
Price Target
No Data
